✦ LIBER ✦

Cost-Effectiveness of Letrozole Versus Tamoxifen as Initial Adjuvant Therapy in Hormone Receptor–Positive Postmenopausal Women with Early-Stage Breast Cancer

✍ Scribed by Thomas E. Delea; Jon Karnon; Oleg Sofrygin; Simu K. Thomas; Natalie L. Papo; Victoria Barghout

Book ID: 115075741
Publisher: CIG Media Group, LP.
Year: 2007
Tongue: English
Weight: 194 KB
Volume: 7
Category: Article
ISSN: 1526-8209
DOI: 10.3816/cbc.2007.n.018

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of letrozole versus t

Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective

✍ Thomas E. Delea; Khalid El-Ouagari; Jonathan Karnon; Oleg Sofrygin 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 301 KB

PCN32 COST-EFFECTIVENESS ANALYSIS OF LET

PCN32 COST-EFFECTIVENESS ANALYSIS OF LETROZOLE VERSUS TAMOXIFEN AS INITIAL ADJUVANT THERAPY IN HORMONE-RECEPTOR POSITIVE POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER IN THE UK

✍ J Karnon; TE Delea; NL Papo; V Barghout; SK Thomas; SR Johnston 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB

P181 Cost-effectiveness analysis of letr

P181 Cost-effectiveness analysis of letrozole vs. tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer: the Belgian perspective

✍ J. Karnon; M. Berli`ere; H. Depypere; L. Dirix; G. Jerusalem; P. Neven; R. Parid 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 57 KB

341 POSTER Letrozole is cost-effective v

341 POSTER Letrozole is cost-effective versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer: BIG-1-98

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 148 KB

0242 Cost effectiveness analysis of letr

0242 Cost effectiveness analysis of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive breast cancer

✍ T. Hashem; M. Al-Sherbini; N. Abd El-Bary; M. Swiha 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Benefit and projected cost-effectiveness

Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor–positive breast cancer

✍ Bruce E. Hillner 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 1 views

## Abstract ## BACKGROUND Women who have estrogen receptor (ER)‐positive disease with postmenopausal onset and who receive tamoxifen as standard adjuvant treatment constitute the largest subgroup of patients with breast cancer. Recent data from the ATAC (‘Arimidex, Tamoxifen Alone or in Combinatio